The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MAGNIFY: A phase 3B, randomized trial of lenalidomide plus rituximab induction and maintenance therapy followed by lenalidomide single-agent versus rituximab maintenance in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL).
David J Andorsky
Research Funding - Celgene
Patricia E Cataruozolo
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Jorge L Mouro
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Ju Li
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Pierre Fustier
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Kenneth A. Foon
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Jeff Porter Sharman
Consultant or Advisory Role - Celgene
Research Funding - Celgene